YB-1 was reported to interact with the X-linked ribosomal protein S4 (RPS4X), driving cisplatin sensitivity in breast cancer cell lines7, and poor outcomes in ovarian8 and bladder cancer9. Here, RPS4X is linked to breast carcinoma.